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Abstract
Development of targeted therapeutics for hepatocellular carcinoma (HCC) remains a major
challenge. The ubiquitination modulator COP1 regulates p53 activity by ubiquitination and it is
frequently overexpressed in human HCC. In this study we tested the hypothesis that COP1 blockade
by siRNA-mediated inhibition could affect the course of HCC progression. The COP1 isoform
COP1-1 was selected as the most effective target for siRNAs in terms of growth inhibition and
apoptotic induction in several HCC cell lines. Growth inhibition occurred in HCC cells that retained
wild-type p53 or expressed mutant p53 (Y220C or R249S), whereas p53 null Hep3B cells were
resistant. Microarray expression analysis revealed that the anti-proliferative effects of COPI-1
blockade were driven by a common subset of molecular alterations including a p53-associated
functional network. In an orthotopic mouse xenograft model of HCC, systemic delivery of a modified
COP1 siRNA by stable nucleic-acid-lipid particles (SNALP) suppressed neoplastic growth in liver
without unwanted immune responses. Our findings offer a first proof of principle that COP1 can be
a promising target for systemic therapy of HCC.
Introduction
HCC is the third most lethal neoplasm causing an estimated 600,000 deaths annually (1). In
the United States the incidence of HCC has doubled over the past two decades, with only 30–
40% of patients being eligible for curative treatments due to the late diagnosis, underlying liver
disease and lack of effective treatment options (2–4). HCCs are phenotypically and genetically
heterogeneous tumors driven by diverse molecular mechanisms (5). However, HCCs exhibit
certain common traits selected through genomic and epigenetic alterations (6,7). Identification
of both common and subclass specific genomic alterations may provide an opportunity for
treatment of HCC through targeted therapy (8).
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We have previously observed that COP1, an E3-ubiquitin ligase also known as RFWD2, is
generally overexpressed in human HCC and could accurately predict patient survival (9). Even
though the overall biological role of the mammalian COP1 is yet to be defined, several
functions have been elucidated (10). In particular, COP1 has been shown to act as a negative
regulator of p53 via ubiquitination (11). Given the significance of p53 and the altered
expression of COP1 in human cancer, we have tested whether the targeting of COP1 could
affect the course of HCC progression. Here we report that siRNA-mediated knockdown of
COP1 inhibited proliferation and induced apoptosis in HCC cells through common molecular
alterations. We also show that systemic silencing of COP1 effectively suppressed human HCC
cell growth in orthotopic xenograft mouse model, suggesting that COP1 is a promising target
for systemic HCC therapy.
Materials and Methods
Cell lines and siRNA treatment
PLC, Hep3B, and HepG2 obtained from the American Type Culture Collection (ATCC), Huh7
from Riken Cell Bank (deposited by Dr. Nam-Ho Huh) and Huh1 from Health Science
Research Resource Bank were passaged for fewer than 6 months. ATCC performed cell line
authentication using DNA fingerprinting by short tandem repeat analysis. Riken and Health
Science Research Resource cell banks did not provide information on method of authentication.
All cell lines were karyotyped upon receipt for future reference. All native siRNA duplexes
used for in vitro studies were chemically synthesized by Ambion. Cells were transiently
transfected with 15 nM control siRNA (Negative Control #1) or COP1-specific siRNA
complexed with Lipofectamine 2000 (Invitrogen). 2’OMe-modified siRNA COP1-4/7 and β
gal478 were synthesized and annealed by Integrated DNA Technologies, and formulated into
SNALP suitable for in vivo delivery to liver as described (12–14). A list of siRNAs is provided
in Supplementary Table 1. Vybrant MTT Cell Proliferation Assay (Invitrogen) and ApoStrand
ELISA Apoptosis Detection Kit (Biomol International) were used to evaluate the biological
effects of siRNA treatment. qRT-PCR and immunoblotting were performed using standard
methods (Supplementary Material and Methods).
Cytokine ELISA
The production of cytokines in culture supernatant of mouse Flt3L dendrocytes or in mouse
serum was measured by sandwich ELISA kits for IFN-α , IFN-β (PBL Biomedical
Laboratories) and IL-6 (BD Biosciences).
Systemic administration of SNALP-formulated siRNA in vivo.
Animals were housed in an AAALAC facility and cared for in accordance with the guidelines
from the Animal Care and Use Committee at the National Cancer Institute, NIH. Huh7-luc+
(5 × 105) or HepG2-luc+ (7 × 105) cells were injected into the splenic pulp of 6-week-old male
SCID/Beige mice (Charles River). SNALP-formulated siRNAs (2 mg/kg) were injected into
the lateral tail vein four times with a 3-day interval. Tumor growth was monitored by
bioluminescence imaging for 4-weeks with 3–4 day intervals using an IVIS Imaging System
(Supplementary Material and Methods).
Microarray experiments
Microarray was performed on human Ref-8v3 microarrays (illumina) as recommended by the
manufacture. RNAs were isolated 48 h after the transfection of NCsiRNA or COP1-1siRNA
to Huh7, HepG2 and Hep3B cells. Detailed procedures and pathway analysis are described in
Supplementary Materials and Methods. The complete microarray data have been submitted to
Lee et al. Page 2
Cancer Res. Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gene Expression Omnibus database with accession number GSE21955
(http://www.ncbi.nlm.nih.gov/geo).
Results and Discussion
Silencing of COP1 inhibits proliferation and induces apoptosis of human HCC cells
To examine the biological effects of COP1 knockdown, two HCC cell lines with wild type
(wt) p53 (HepG2) and mutant (mt) p53 (Huh7: Y220C) were treated with three COP1-specific
(COP1-1, COP1-2 and COP1-3) siRNA for 4 days and analyzed for growth inhibition. This
screen identified COP1-1 as the most potent siRNA. COP1 knockdown caused a strong
reduction in growth rate in both cell lines which ranged between 84–88% and was paralleled
by a similar degree of target mRNA silencing (Fig. 1A, Supplementary Fig. 1A). The Western
blot experiments confirmed that the protein levels of COP1 were also reduced in COP1siRNA-
treated HCC cell lines (Supplementary Fig. 1B and C)
Analysis of cell cycle progression by FACS showed that COP1-1siRNA increased the G0/G1
population while decreasing the fraction of cells in G2/M phase in both Huh7 and HepG2 cells,
consistent with a cell cycle arrest in G1-phase (Fig. 1B). Furthermore, COP1 treatment caused
a strong induction of apoptotic cell death (Fig. 1C). Significantly, COP1 depletion was similarly
effective in suppressing the growth of two additional HCC cell lines, Huh1 and PLC/PRF/5,
expressing wt and mt p53 (R249S), respectively, whereas p53-null Hep3B cells were
significantly more resistant (Fig. 1D).
Microarray analysis of global gene expression changes in COP1 siRNA-treated HCC cell lines
To understand the mechanism of action of COP1 in HCC cells, we performed expression profile
analysis. For this purpose, three HCC cell lines with different genetic status of p53 were treated
with either NCsiRNA or COP1-1siRNA for 48 hours and subjected to illumina microarray
analysis. The number of differentially expressed genes which displayed more than a 2-fold
change was 522 (179 up- and 343 down-regulated genes) and 462 (167 up- and 295 down-
regulated genes) in COP1siRNA-treated HepG2 and Huh7 cells, respectively. Consistent with
COP1 function as a negative regulator of p53 protein (11), several genes affected by COP1
inactivation were known/putative targets of p53. As expected, p53 was among the predominant
pathways affected by differentially regulated genes by COP1 knockdown in HepG2 and Huh7
cells (Fig. 2A and B). In HepG2 cells, COP1 silencing increased expression of apoptosis-related
(NOS2A and BIK) and anti-proliferative (BTG2, GLIPR1 and FHL2) genes which was
paralleled by down-regulation of key molecules involved in a wide range of cellular responses
to hypoxia (HIF1α ), growth (IGF1R, ABL1, POLK) and differentiation (HDAC5). Consistent
with phenotypic changes, COP1-depleted Huh7 cells also displayed changes in p53-associated
group of genes functionally involved in regulation of apoptosis, growth and differentiation
including CASP6, GLIPR1, FHL2, GADD45A, ABL1, BCL6, and GDF15 genes. However,
COP1 inactivation increased the p53 protein levels only in HepG2 cells with wt p53 and did
not affect the p53 abundance in Huh7 cells which carry Y220C mutation increasing p53 protein
stability (Supplementary Fig. 1B and C) (15). At present, the knowledge on the molecular basis
for mutant p53 gain of function is limited (16), and we cannot exclude that COP1 inactivation
does not activate classical p53 pathway in Huh7 cells or has an indirect effect on p53 pathway
through intermediate molecules.
To further explore the molecular mechanisms of COP1 response, we have generated a common
COP1 knockdown signature consisting of 78 deregulated genes (Supplementary Table 2) Using
the Ingenuity Pathway Analysis software, we then identified common statistically significant
pathway networks (score >19) which were strongly associated with NF-κB, HNF4α , p53 and
TNF, suggesting that molecular alterations in the diverse oncogenic pathways may
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cooperatively result in the growth inhibition of HCC cells in response to COP1 inactivation
(Supplementary Fig. 2, Supplementary Table 3). Given the statistical and biological relevance
to the study, we focused on the p53 network (#3). Our results showed that despite a limited
gene to gene overlap, the expressions of seven genes, known to be associated with p53 pathway,
such as FOXO3, NEDD8, TAP1, RFWD2 (COP1), FHL2, ABL1 and GLIPR1, was commonly
deregulated (Fig. 2C). Knockdown of COP1 in p53-null Hep3B cells did not affect any of these
genes, except for the RFWD2 (COP1) target gene (Fig. 2C). The p53-null cells were also
significantly more resistant to growth inhibition caused by COP1 silencing, suggesting that
COP1 knockdown phenotype is associated with p53 function. In particular, our microarray
analysis identified a common upregulation of glioma pathogenesis-related protein 1 (GLIPR1)
(Fig. 2C and D). GLIPR1 is a novel p53 target gene shown to exert tumor suppressor activities
through upregulation of ROS-JNK pathway in p53+/+ and p53+/− genetic background (17).
Indeed, increase in GLIPR1 protein and JNK phosporylation were found only in Hun7 and
HepG2 but not in p53-null Hep3B cells, suggesting that activation of GLIPR1/JNK pathway
might be a common mechanism of growth inhibition and apoptotic induction engaged by COP1
inactivation.
Systemic delivery of COP1siRNA by SNALP suppresses liver tumor growth in vivo
Ultimately, we confirmed the therapeutic potential of COP1 in vivo, using two human xenograft
models. First, statistically significant inhibition of tumor growth was observed in a
subcutaneous model of transplantation in nude/athymic mice (Supplementary Fig. 3). Direct
injections of native COP1-1siRNA into the tumors established from Huh7 cells caused a dose-
dependent reduction in tumor mass. As a final validation of antitumor efficacy of COP1 in
vivo, we established an orthotopic xenograft model in SCID/Beige mice using luciferase-
expressing HCC reporter cell lines and a SNALP formulation optimized for delivery of siRNA
into liver. Recently, we have described the development of SNALP as an effective systemic
delivery vehicle for targeting siRNA to murine and primate liver as well as solid tumors and
have demonstrated robust therapeutic silencing of endogenous hepatocyte, tumor and viral
gene transcripts in the absence of any measurable immune response (12–14). To prevent
immune activation by the formulated siRNA, the native COP1-1 and non-targeting control β
gal478 sequences were modified by selective incorporation of 2’-O-methyl (2’OMe) uridine
or guanosine nucleosides into siRNA duplex (18). COP1-4/7 was selected as the most effective
2’OMe-modified siRNA for growth inhibition (>70%) and target mRNA silencing (>90%)
(Fig.3A and B). The modified COP1 4/7 caused minimal activation of cytokines, such as IFN-
α and IL-6 (Fig. 3C). Additionally, systemic injection of SNALP-COP1 4/7 did not increase
the production of IFN-β in serum collected 48 h after delivery (Fig. 3D). Four intravenous
injections of SNALP-COP1 4/7 significantly suppressed the growth of Huh7-luc+- or HepG2-
luc+-derived tumors in liver as compared to a control group receiving SNALP-β gal478 based
on bioluminescence imaging and microscopic examination (Fig. 4). In both cases, a dose of 2
mg/kg showed a potent and long lasting effect resulting in a more than 12- and 9-fold decrease
in tumor growth, respectively, 10 days after the last treatment and thereby exceeding the NCI
criteria for promising therapeutic compounds. In conclusion, this is the first demonstration that
COP1 is an important regulator of HCC growth and survival, and may represent a promising
molecular target for systemic therapy of a wide spectrum of human HCC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
siRNA knockdown of COP1 inhibits growth of HCC cells in vitro. A, Huh7 and HepG2 cells
were transfected with COP1-specific siRNAs and examined at 4 days by MTT assay (top) and
at 2 days by real-time RT-PCR (bottom). B, Cell cycle analysis 2 days after transfection. C,
Detection of apoptosis 3 days after transfection. D, Effect of COP1-1siRNA knockdown on
survival of HCC cells. The data are calculated relative to the negative control siRNA (NC) and
presented as the mean ± SD of triplicate experiments. Statistical analysis was performed using
Bootstrap t-test. NT, No treatment, COP1-1, COP1-2 and COP1-3 specific siRNA are shown
as 1-1, 1-2, and 1-3. **, P < 0.01.
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Figure 2.
Changes in gene expression following COP1 knockdown. A,B, Heat-map overview of genes
up- and downregulated at 48 h after COP1 inactivation in Huh7 (A) and HepG2 (B) cells. The
means of the intensity log ratios from COP1-1siRNA treated cells were calculated relative to
the negative control siRNA-treated cells. P < 0.01 by Bootstrap t-test. Expression targets of
p53 are shown to the right. C, Fold-changes of genes commonly dysregulated and functionally
associated with p53. D, Western blot analysis of GLIPR1 and phosphorylated JNK in Huh7,
HepG2, and Hep3B cells that were untreated or treated with the indicated siRNA for 48 h.
Actin was included as a loading control.
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Figure 3.
Selection of COP1 4/7siRNA for in vivo application based on the inhibition of tumor cell
growth and minimal cytokine induction. A, Inhibition of Huh7-luc+ cell growth after
transfection of SNALP-formulated COP1-1 (native) or COP1 4/7 siRNA (a modified variant).
The siRNA transfectants were examined by MTT assay at 4 days after treatment. B, Real-Time
RT-PCR analysis of COP1 gene expression in Huh7-luc+ cells treated with the indicated
siRNA. **, P < 0.01 (n=3) by Bootstrap t-test. C, Quantification of cytokines after luciferase
(LUC) or COP1 targeting. Culture supernatants of Flt3L-derived dendrocytes were assayed
for IFN-α and IL-6 using ELISA at 24 h after siRNA treatment. Data are shown are the means
± SD of triplicate experiments. D, Serum levels of IFN-β and downregulation of COP1 protein
levels in Huh7-derived tumors (inset) 48 h after a single i.v. administration of encapsulated
siRNA (2 mg/kg) targeting β-galactosidase (β gal) or COP1 into immunodeficient mice. Each
bar represents the mean picogram of IFN-β ± SD of duplicate experiments. NS, normal serum,
S, SNALP.
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Figure 4.
Systemic delivery of COP1 4/7siRNA by SNALP suppresses human HCC growth in orthotopic
xenograft model. SCID/beige mice received Huh7-luc+ (A) and HepG2-luc+ (B) cells through
intrasplenic injection resulting in tumorous growth in the liver. Mice were randomly assigned
either to control (SNALP-β gal478) or treatment (SNALP-COP1 4/7) group based on the
intensity of bioluminescence before initiation of COP1 4/7siRNA therapy at day 8 for Huh7
and day 11 day for HepG2. Two mg/kg of SNALP-β gal478 and SNALP-COP1 4/7 were
injected into tail vein at the time indicated. Representative in vivo bioluminescence imaging
of Huh7- and HepG2-xenografts are shown on the left. Images were set at the same pseudocolor
scale to show the relative bioluminescence changes over time. Quantification of
bioluminescence (middle panels). The total flux is plotted as photon/second. *, P < 0.05 (n=8
vs. n=5) by Student’s t-test; **, P < 0.01, (n=8 vs. n=6) by Mann-Whitney U-test.
Histopathological evaluation (right panels). Representative photos of gross liver morphology
at 28 days after transplantation are shown. H&E staining, original magnification X50.
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